Brief: Antengene Corp Announces NMPA Approval Of IND Applications For Phase Ib/Ii Clinical Trial Of Eltanexor In Advanced Solid Tumors
14/05/2021 02:21
May 14 (Reuters) - Antengene Corporation Ltd 6996.HK :
* RECEIVED APPROVAL OF IND APPLICATION BY NMPA FOR PHASE
IB/II
CLINICAL TRIAL OF ELTANEXOR IN ADVANCED SOLID TUMORS IN CHINA
Source text for Eikon: ID:nHKS3x71w6
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106